意大利重症监护病房获得性念珠菌血症的流行病学、耐药模式与结局:GIVITI网络2020-2024年洞察
该多中心研究基于PROSAFE网络,分析2020-2024年155个意大利ICU中ICU获得性念珠菌血症的趋势。在95,662例高危入院(ICU停留≥48小时)中,发生373例(3.9‰)。与ICU获得性细菌性血流感染相比,念珠菌血症患者ICU住院时间(32 vs 24天)和住院时间(44 vs 36天)更长,ICU内病死率(41.3% vs 28.7%)和院内病死率(50.3% vs 34.1%)更高(p<0.001)。白色念珠菌占47.2%,近平滑念珠菌占33.0%,后者常对氟康唑耐药(53.7%)。氟康唑耐药不增加病死率,但延长ICU住院时间(36 vs 31天;p=0.016)。非导管相关感染(197/373,52.8%)院内病死率更高(57.0% vs 42.9%;p=0.007)。结论支持加强监测、导管护理和早期抗真菌治疗。
要点
- 在95,662例高危ICU入院中,ICU获得性念珠菌血症373例(3.9‰),ICU内病死率41.3%,院内病死率50.3%。
- 与ICU获得性细菌性血流感染相比,念珠菌血症ICU住院时间32 vs 24天、住院时间44 vs 36天,均更长(p<0.001)。
- 近平滑念珠菌占33.0%,其中53.7%对氟康唑耐药;耐药者ICU住院时间36 vs 31天(p=0.016),但病死率未增加。
- 非导管相关感染占52.8%(197/373),院内病死率57.0% vs 42.9%(p=0.007),预后更差。
- 作者认为 findings 支持加强监测、导管护理和早期抗真菌治疗。
适用人群与场景
- 意大利155个ICU中ICU获得性念珠菌血症患者;高危入院定义为ICU停留≥48小时。
研究设计与关键结果
- 多中心前瞻性观察研究(PROSAFE网络),分析2020-2024年155个意大利ICU中179,590例入院,其中95,662例为高危入院(ICU停留≥48小时)。
- ICU获得性念珠菌血症373例,占高危入院的3.9‰。
- 与ICU获得性细菌性血流感染相比:ICU住院时间32 vs 24天,住院时间44 vs 36天(p<0.001);ICU内病死率41.3% vs 28.7%,院内病死率50.3% vs 34.1%(p<0.001)。
- 菌种分布:白色念珠菌47.2%,近平滑念珠菌33.0%;近平滑念珠菌中氟康唑耐药占53.7%。
- 氟康唑耐药组与非耐药组比较:病死率未增加,但ICU住院时间延长(36 vs 31天;p=0.016)。
- 非导管相关感染197/373例(52.8%),院内病死率57.0% vs 42.9%(p=0.007)。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察研究(PROSAFE网络)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为研究结果支持加强监测、导管护理和早期抗真菌治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: This multicenter study focuses on the latest (2020-2024) trends in candidemia in 155 Italian ICUs, stressing its frequency and lethality, with a shift toward non-albicans, fluconazole-resistant species, namely C. parapsilosis. In this study, resistance to fluconazole prolonged ICU stays without increasing mortality, while non-catheter-related episodes had a more severe prognosis.
RATIONALE: Candidemia is the leading fungal bloodstream infection (BSI) in the ICU and carries high mortality. After the COVID-19 pandemic, non-albicans, fluconazole-resistant species increased in Europe, yet contemporary ICU-acquired data are scarce. The primary outcome of this study was to evaluate the incidence of ICU-acquired candidemia per 1,000 "at risk" ICU admissions (ICU length of stay [LOS] ≥ 48 h). Secondary analyses compared ICU-acquired candidemia with ICU-acquired bacterial BSI and assessed species distribution, fluconazole susceptibility, and outcomes by fluconazole resistance and by source of infection.
METHODS: Data were drawn from the PROSAFE network, a prospective multicentric observational project conducted across 192 Italian ICUs (2014-2023).
RESULTS: Among 179,590 ICU admissions, 95,662 were at risk. ICU-acquired candidemia occurred in 373 patients (3.9‰ of at-risk admissions). Compared with ICU-acquired bacterial BSI, candidemia patients had longer intra-ICU and hospital LOS (32 vs 24 days and 44 vs 36 days, respectively; p < 0.001) and higher mortality (intra-ICU 41.3% vs 28.7%; intra-hospital 50.3% vs 34.1%; p < 0.001). Candida albicans was isolated in 47.2% of episodes, followed by Candida parapsilosis at 33.0%; the latter is often fluconazole-resistant (53.7%). Mortality did not increase in fluconazole-resistant episodes, but ICU LOS did (36 vs 31 days; p = 0.016). Non-catheter-related infections (197/373, 52.8%) had higher intra-hospital mortality rates (57.0% vs 42.9%; p = 0.007).
CONCLUSIONS: ICU-acquired candidemia in Italy remains frequent and lethal, with a worrisome shift in epidemiology and resistance; the latter prolongs ICU stay without increasing mortality. Non-catheter-related episodes had a poorer prognosis. Findings support enhanced surveillance, catheter care, and earlier antifungal therapy.
参考来源
- Scaglione G, Colaneri M, Offer M, et al. Epidemiology, resistance patterns, and outcomes of candidemia acquired in Italian intensive care units: insights from the GIVITI network (2020-2024). Crit Care. 2026. PMID: 41952228. doi:10.1186/s13054-026-05886-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。